We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: tenecteplase
MedXY News
EnglishTag

tenecteplase

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationcritical carebiomarkersclinical trialsartificial intelligenceHypertensionCardiologyoncologytype 1 diabetespublic healthMortalitydiabetesAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Identifying and Mitigating Risk Factors for Intracranial Haemorrhage Following Tenecteplase Fibrinolysis in Acute Myocardial Infarction
CardiologytenecteplaseRisk Prediction

Identifying and Mitigating Risk Factors for Intracranial Haemorrhage Following Tenecteplase Fibrinolysis in Acute Myocardial Infarction

By MedXY|Sep 23, 2026

This study evaluates risk factors for intracranial haemorrhage after tenecteplase fibrinolysis in STEMI patients, developing a prediction model highlighting age, blood pressure, sex, weight, and dose interactions as key determinants.

Early Recanalization in Distal and Medium Vessel Occlusion Strokes: Tenecteplase vs Alteplase
Neurologydistal vessel occlusion
recanalization

Early Recanalization in Distal and Medium Vessel Occlusion Strokes: Tenecteplase vs Alteplase

By MedXY|Sep 15, 2026

In patients with distal and medium vessel occlusion strokes, tenecteplase achieves higher early recanalization rates and reduces early infarct growth compared to alteplase, supporting its preferential use in this clinical setting.

Tenecteplase Efficacy in Distal Cerebral Artery Occlusions: Insights From the Secondary Analysis of the TASTE Randomized Clinical Trial
Clinical Updatesalteplaseischemic stroke

Tenecteplase Efficacy in Distal Cerebral Artery Occlusions: Insights From the Secondary Analysis of the TASTE Randomized Clinical Trial

By MedXY|Sep 6, 2026

Secondary analysis of the TASTE trial reveals tenecteplase confers superior functional outcomes versus alteplase in patients with distal middle cerebral artery occlusions, supporting its use in more peripheral ischemic stroke territories.

Baseline Ischemic Burden Influences Tenecteplase Benefit Before Thrombectomy in Acute Stroke: Insights from the BRIDGE-TNK Trial
NeurologyIntravenous thrombolysistenecteplase

Baseline Ischemic Burden Influences Tenecteplase Benefit Before Thrombectomy in Acute Stroke: Insights from the BRIDGE-TNK Trial

By MedXY|Aug 22, 2026

A post hoc analysis of the BRIDGE-TNK trial reveals that intravenous tenecteplase before endovascular thrombectomy significantly improves functional independence in acute large-vessel occlusion stroke patients with extensive baseline ischem

Successful Recanalization Boosts Functional Recovery in Minor Ischemic Stroke: Insights from the TEMPO-2 Trial
Neurologyfunctional outcomeMinor ischemic stroke

Successful Recanalization Boosts Functional Recovery in Minor Ischemic Stroke: Insights from the TEMPO-2 Trial

By MedXY|Jun 27, 2026

Secondary analysis of the TEMPO-2 trial reveals that successful recanalization significantly improves 90-day functional outcomes in minor ischemic stroke patients with proven occlusion, with tenecteplase markedly enhancing recanalization ra

Standard-Dose Tenecteplase vs Low-Dose Alteplase for Acute Ischemic Stroke From Large-Vessel Occlusion: A Randomized Clinical Trial
Neurologyacute ischemic strokealteplase

Standard-Dose Tenecteplase vs Low-Dose Alteplase for Acute Ischemic Stroke From Large-Vessel Occlusion: A Randomized Clinical Trial

By MedXY|Jun 3, 2026

In a randomized trial of large-vessel-occlusion stroke, standard-dose tenecteplase improved early reperfusion before thrombectomy compared with low-dose alteplase, with similar safety and functional outcomes.

Standard-Dose Tenecteplase vs Low-Dose Alteplase for Acute Ischemic Stroke From Large-Vessel Occlusion: A Randomized Clinical Trial
Neurologyacute ischemic strokealteplase

Standard-Dose Tenecteplase vs Low-Dose Alteplase for Acute Ischemic Stroke From Large-Vessel Occlusion: A Randomized Clinical Trial

By MedXY|Jun 3, 2026

In patients with large-vessel-occlusion stroke undergoing thrombectomy, standard-dose tenecteplase achieved more early reperfusion than low-dose alteplase, with similar safety and functional outcomes.

Tenecteplase Improves 90-Day Functional Outcomes in Basilar Artery Occlusion Within a 24-Hour Window: Results from TRACE-5
Neurologyischemic strokeTắc động mạch đáy

Tenecteplase Improves 90-Day Functional Outcomes in Basilar Artery Occlusion Within a 24-Hour Window: Results from TRACE-5

By MedXY|Feb 16, 2026

The TRACE-5 trial demonstrates that tenecteplase significantly improves functional outcomes for patients with basilar artery occlusion within 24 hours of onset, offering a safe and effective extension of the therapeutic window for this high

Expanding the Thrombolysis Window: Tenecteplase Improves Outcomes in Late-Window Non-Large Vessel Occlusion Stroke
Neurologyischemic strokeNeuroimaging

Expanding the Thrombolysis Window: Tenecteplase Improves Outcomes in Late-Window Non-Large Vessel Occlusion Stroke

By MedXY|Feb 8, 2026

The OPTION trial reveals that tenecteplase administered 4.5 to 24 hours post-stroke in patients with non-large vessel occlusion and salvageable tissue significantly improves functional recovery, although it carries a higher risk of symptoma

Tenecteplase Fails to Improve Visual Outcomes in Acute Central Retinal Artery Occlusion: Results from the TenCRAOS Trial
Neurologycentral retinal artery occlusionophthalmology

Tenecteplase Fails to Improve Visual Outcomes in Acute Central Retinal Artery Occlusion: Results from the TenCRAOS Trial

By MedXY|Feb 2, 2026

The TenCRAOS trial demonstrated that intravenous tenecteplase administered within 4.5 hours of acute central retinal artery occlusion does not improve vision recovery compared to aspirin and carries significant safety risks, including fatal

Tenecteplase Outperforms Alteplase in Mechanical Heart Valve Thrombosis: Insights from the TENET Trial
CardiologyCardiologyprosthetic valve thrombosis

Tenecteplase Outperforms Alteplase in Mechanical Heart Valve Thrombosis: Insights from the TENET Trial

By MedXY|Jan 16, 2026

The TENET randomized clinical trial reveals that tenecteplase bolus administration achieves significantly higher thrombolytic success rates and shorter hospital stays compared to alteplase infusion for mechanical prosthetic valve thrombosis

Reevaluating Intravenous Tenecteplase in Minor Disabling Stroke: Insights from the TEMPO-2 Secondary Analysis
NeurologyIntravenous thrombolysisMinor ischemic stroke

Reevaluating Intravenous Tenecteplase in Minor Disabling Stroke: Insights from the TEMPO-2 Secondary Analysis

By MedXY|Oct 29, 2025

A secondary analysis of the TEMPO-2 trial shows that intravenous tenecteplase does not improve 90-day outcomes in minor disabling stroke defined by NIHSS scores, highlighting the need to reconsider thrombolysis in this patient population.

Tenecteplase in Modern Stroke Care: Comparative Insights from Recent Chinese Clinical Trials
Neurologyclinical trialsstroke

Tenecteplase in Modern Stroke Care: Comparative Insights from Recent Chinese Clinical Trials

By MedXY|Sep 30, 2025

Three major Chinese trials examine intravenous and intra-arterial tenecteplase as adjuncts to thrombectomy in acute large-vessel occlusion stroke, revealing functional benefit with intravenous use before thrombectomy but not after reperfusi

Intra-arterial Tenecteplase After Thrombectomy for Acute Stroke: Interpreting the ANGEL-TNK Randomized Clinical Trial
Clinical Updatesclinical trialstroke

Intra-arterial Tenecteplase After Thrombectomy for Acute Stroke: Interpreting the ANGEL-TNK Randomized Clinical Trial

By MedXY|Jul 31, 2025

The ANGEL-TNK trial found that intra-arterial tenecteplase after successful endovascular thrombectomy improved excellent neurological outcomes at 90 days without increasing bleeding or mortality, but secondary outcomes showed no significant

Intra-arterial Tenecteplase After Thrombectomy for Acute Stroke: Interpreting the ANGEL-TNK Randomized Clinical Trial
Clinical Updatesclinical trialstroke

Intra-arterial Tenecteplase After Thrombectomy for Acute Stroke: Interpreting the ANGEL-TNK Randomized Clinical Trial

By MedXY|Sep 30, 2025

The ANGEL-TNK trial found that intra-arterial tenecteplase after successful endovascular thrombectomy improved excellent neurological outcomes at 90 days without increasing bleeding or mortality, but secondary outcomes showed no significant

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure